The U.S. Food and Drug Administration has been collecting public input on CBD (cannabidiol) to find out how cannabis and its compound are regulated, as the World Health Organization is working to examine international regulations of the compound.

To discuss the properties of CBD on a closer level, WHO’s Expert Committee on Drug Dependence (ECDD) will host its 39th meeting in Geneve, Switzerland, in November. The meeting will collect input on CBD and 16 other drugs as well.

More than 6,400 comments have been submitted so far, the vast majority of which were about CBD, according to a review by The Cannabist. The comments will first be reviewed by U.S. Health & Human Services, which is expected to provide its input on the 17 substances on aspects such as medical use, scientific use, current control status, misuse, and cultural or religious use.

HHS will hold off on making its own recommendations and providing its position on the international control of the substances, until further determinations are submitted to the Commission on Narcotic Drugs.

Although the vast majority of the 17 substances under examination at November’s meeting are categorized as WHO’s “substances under surveillance,” CBD does not make the list, as it shows potential medical benefit versus potential public harm.

Cannabidiol (CBD) is one of the active cannabinoids identified in cannabis. CBD has been shown to be beneficial in experimental models of several neurological disorders, including those of seizure and epilepsy. In the United States, CBD-containing products are in human clinical testing in three therapeutic areas, but no such products are approved by FDA for marketing for medical purposes in the United States. CBD is a Schedule I controlled substance under the CSA.

In addition to the discussion of CBD on an international level at the meeting, American researchers will also address the restrictive barriers that revolve around studying cannabis and its components, such as CBD.